Heligenics
Private Company
Funding information not available
Overview
Heligenics is a private, pre-revenue biotech platform company pioneering a genetics-inspired approach to biologic drug discovery. Its core innovation is the GigaAssay™, a high-throughput, cell-based screening platform capable of analyzing hundreds of thousands of biologic variants simultaneously to map function and identify optimized drug candidates. The company has generated a substantial preclinical pipeline focused on interferon biobetters for autoimmune diseases and cancer, and is actively developing GLP-1 variants for the metabolic disorder space. Heligenics operates primarily through partnerships with pharmaceutical and biotechnology companies to advance and license its discovered assets.
Technology Platform
GigaAssay™: A high-content, cell-based screening platform that uses DNA barcoding to functionally analyze massive libraries (hundreds of thousands) of biologic variants simultaneously in human cells, generating functional maps (MEGA-Maps™) to guide drug discovery.
Opportunities
Risk Factors
Competitive Landscape
Heligenics competes with a broad array of protein engineering and display technologies (e.g., phage/yeast/mammalian display) and a growing number of AI/ML-based biologic design companies. Its differentiation claims to be the scale and cellular context of its functional screening, but it must prove this translates to a tangible advantage in speed, cost, or candidate quality.